Kinnate Biopharma (KNTE)

Kinnate Biopharma (KNTE) Financial Statements


Kinnate Biopharma Financial Overview

Kinnate Biopharma's market cap is currently ―. The company's EPS TTM is $-2.819; its P/E ratio is -0.49; Kinnate Biopharma is scheduled to report earnings on November 9, 2023, and the estimated EPS forecast is $-0.66. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue---$ 0.00$ 0.00
Gross Profit-----
EBIT$ -31.92M$ -34.65M$ -32.73M$ -31.37M$ -27.41M
EBITDA$ 0.00$ -35.19M$ -32.84M$ -31.19M$ -27.23M
Net Income Common Stockholders$ -31.92M$ -32.94M$ -31.61M$ -30.74M$ -27.07M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 184.70M$ 200.98M$ 227.20M$ 230.98M$ 233.00M
Total Assets$ 216.18M$ 243.88M$ 278.83M$ 302.13M$ 323.90M
Total Debt$ 3.70M$ 3.95M$ 4.18M$ 4.42M$ 4.54M
Net Debt$ -181.00M$ -197.03M$ -223.02M$ -226.56M$ -228.46M
Total Liabilities$ 18.52M$ 21.12M$ 20.36M$ 18.79M$ 15.17M
Stockholders Equity$ 197.64M$ 222.76M$ 223.47M$ 248.34M$ 273.73M
Cash Flow-
Free Cash Flow-$ -27.73M$ -23.84M$ -20.72M$ -24.09M
Operating Cash Flow-$ -27.72M$ -23.75M$ -20.66M$ -23.54M
Investing Cash Flow-$ 55.42M$ 17.57M$ 16.96M$ 23.28M
Financing Cash Flow-$ -9.12M$ 193.00K$ 190.00K$ 652.00K
Currency in USD

Kinnate Biopharma Earnings and Revenue History

Kinnate Biopharma Debt to Assets

Kinnate Biopharma Cash Flow

Kinnate Biopharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis